News
ANIX
3.510
-1.68%
-0.060
HC Wainwright & Co. Reiterates Anixa Biosciences (ANIX) Buy Recommendation
NASDAQ · 05/23 23:42
The Latest Analyst Ratings for Anixa Biosciences
Benzinga · 05/23 16:01
H.C. Wainwright Reaffirms Their Buy Rating on Anixa Biosciences (ANIX)
TipRanks · 05/23 10:25
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Benzinga · 05/23 10:17
Alnylam (ALNY) Reports Positive Results From APOLLO-B Study
NASDAQ · 05/22 16:01
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
NASDAQ · 05/22 15:05
Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial
PR Newswire · 05/22 12:30
Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
NASDAQ · 05/18 15:15
Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag
NASDAQ · 05/17 18:19
Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up
NASDAQ · 05/16 11:44
Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
NASDAQ · 05/12 14:04
Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates
NASDAQ · 05/09 14:40
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Seeking Alpha · 04/18 23:13
Expert Ratings for Anixa Biosciences
Benzinga · 04/18 17:01
Chardan Capital Sticks to Their Buy Rating for Anixa Biosciences (ANIX)
TipRanks · 04/18 12:39
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Anixa Biosciences (ANIX), Gamida Cell (GMDA) and Satsuma Pharmaceuticals (STSA)
TipRanks · 04/18 10:30
Chardan Capital Reiterates Buy on Anixa Biosciences, Maintains $9 Price Target
Benzinga · 04/18 09:00
Anixa Biosciences Breast Cancer Vaccine Candidate Has 15% Probability of Success Amid Updated Phase 1 Data, Chardan Says
Anixa Biosciences Breast Cancer Vaccine Candidate Has 15% Probability of Success Amid Updated Phase 1 Data, Chardan Says
MT Newswires · 04/18 05:19
Anixa Biosciences Clarifies Poster Presentation on Company Website
PR Newswire · 04/17 19:27
More
Webull provides a variety of real-time ANIX stock news. You can receive the latest news about Anixa Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. Its vaccine programs include the development of a preventative vaccine against triple-negative breast cancer (TNBC), the lethal form of breast cancer, as well other forms of breast cancer, and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell (CAR- T) technology that is focused on treating ovarian cancer, which is developed at its subsidiary, Certainty Therapeutics, Inc., and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.